Page 4 - Nifty Pharma

Sun Pharma inks MoU with Takeda to introduce gastrointestinal drug in India

Sun Pharmaceutical Industries on Friday said it has inked a licensing pact with Takeda Pharmaceutical Company to commercialise a novel gastrointestinal drug in India. The company has entered into a non-exclusive patent licensing agreement with Takeda to commercialise Vonoprazan tablets in strengths of 10 and 20 mg in India, the Mumbai-based drug major said in a statement. Vonoprazan is a novel, orally active potassium competitive acid blocker (PCAB), used to treat reflux esophagitis and other acid peptic disorders. "Sun Pharma is a leader in gastroenterology and we are excited to introduce Vonoprazan in India under non-exclusive patent license from Takeda," Sun Pharma CEO - India Business Kirti Ganorkar said. The partnership demonstrates the company's commitment to gastrointestinal health by providing patients and healthcare practitioners with a novel treatment option to manage reflux esophagitis and other acid peptic disorders, he added. Gastroesophageal Reflux Disease (GERD) is

Pricing challenge in US biz, rich valuations may weigh on pharma stocks

Among individual players, Aurobindo Pharma, Dr Reddys Labs, and Zydus Lifesciences sourced 48 per cent, 47 per cent, and 46 per cent of their total revenues from the US generics segment, respectively

Why did investors dump Marksans Pharma shares post Q4 results? Know here

Marksans Pharma's net profit fell 4.5 per cent on a year-on-year (Y-o-Y) basis to Rs 78.3 crore in the March quarter of FY24, from Rs 82 crore in the March quarter of FY23

Stock trading guide for today: How to approach pharma, FMCG counters?

Technical indicators such as the RSI, MACD, and Stochastic are showing signs of potential correction and underperformance for the Nifty Pharma index

Nifty Energy on decline, Nifty Pharma range bound: Know what charts suggest

The Nifty Energy Index, currently priced at 38,458.00, is displaying a downward trend in the near term according to the charts

Guide to trade in Nifty Pharma, FMCG indices; check what charts suggest

According to Ravi Nathani, an independent technical analyst, the Nifty Pharma index is quoting close to its ley support at 18,325; hence one may consider a buy on dip strategy here.

Nifty Energy, Pharma: In a downtrend; look to sell on rally, hint charts

According to Ravi Nathani, an independent technical analyst, the Nifty Energy index can be sold with a stop at 40,320.

Analysts favour defensive bets as hedge against equity market downturn

From defensives, Nifty Pharma index has led gains so far in calendar year 2024 with a surge of 11 per cent, followed by Nifty IT, which is up 4 per cent while Nifty FMCG has shed 6 per cent

Near-term weakness likely for Nifty Pharma, Energy: Check trading strategy

Technical indicators such as RSI (Relative Strength Index) and MACD (Moving Average Convergence Divergence) are both displaying a downtrend on charts for Nifty Pharma

Nifty Energy: Look for opportunities to sell on rise; Pharma seems sideways

On the upside, the Nifty Energy index is likely to face resistance around 39,650, says Ravi Nathani, an independent technical analyst.

Nifty Energy to face stiff resistance at 40,000; Pharma seems range-bound

According to Ravi Nathani, an independent technical analyst, the Nifty Energy index is trading in overbought zone, hence some reversal can be anticipated.

Nifty Energy, Pharma: Trading strategies for indices in overbought zone

A trade below 37,968 could prompt a stop-loss trigger for bullish positions on the Nifty Energy index, says Ravi Nathani, an independent technical analyst.

Downtrend on charts for Nifty FMCG, Nifty Pharma: Check key levels

The Nifty FMCG Index reveals a near-term downtrend on charts, with a support level expected around 53,725

Nifty Pharma, Nifty Energy eyeing correction on charts: Check key levels

Technical indicators for Nifty Pharma are aligning with the bearish sentiment as the RSI has declined to 59, signaling a potential downtrend, as per Ravi Nathani

Nifty Energy, Pharma reaching near resistance levels; Check how to trade

Resistance for Nifty Energy index is anticipated around 34,000 and 34,300, signifying potential areas where selling pressure may intensify, as per Ravi Nathani

Nifty Metal weak on charts, Nifty Pharma rangebound: How to trade them?

Only a decisive close above 7,616 in Nifty Metal would indicate a potential reversal, opening the door for further upward movement with the next target at 7,740, says Ravi Nathani

Nifty Metal eyes consolidation, Nifty Pharma trades with negative bias

The advised strategy for the Nifty Metal index is to buy near support levels and sell near resistance

Nifty Metal in overbought zone, Nifty Pharma could see minor correction

Anticipated resistance on charts is around 7,675 for Nifty Metal; the consolidation range for pharma index is between 16,470 and 16,030

Nifty Metal, Nifty Pharma: 'Sell on rise' as charts suggest likely pullback

Technical indicators such as RSI and Stochastic are currently situated in the overbought zone for the Nifty Pharma index, said Ravi Nathani

Time to book profit in Nifty Pharma; Auto index remains bullish

According to Ravi Nathani, an independent technical analyst, stiff resistance for the Nifty Pharma index is anticipated at 15,600 level.